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Abuse of 3,4-methylenedioxymethamphetamine (MDMA) is becomingmore commonworldwide. To date, there is no information
available on stereoselectivity of MDMA protein binding in humans, rats, and mice. Since stereoselectivity plays an important role
in MDMA’s pharmacokinetics and pharmacodynamics, in this study we investigated its stereoselectivity in protein binding. The
stereoselective protein binding of rac-MDMA was investigated using two different concentrations (20 and 200 ng/mL) in human
plasma and mouse and rat sera using an ultrafiltration technique. No significant stereoselectivity in protein binding was observed
in both human plasma and rat serum; however, a significant stereoselective binding (𝑝 < 0.05) was observed inmouse serum. Since
the protein binding of MDMA in mouse serum is considerably lower than in humans and rats, caution should be exercised when
using mice for in vitro studies involving MDMA.
1. Introduction
3,4-Methylenedioxymethamphetamine (MDMA) is a com-
monly abused drug with estimated 18.8 million users world-
wide in 2013 [1]. Acting as a sympathomimetic agent, MDMA
causes acute and chronic side effects such as hyperther-
mia, neurotoxicity, respiratory arrest, and hepatotoxicity [2–
4]. Metabolism of MDMA occurs primarily through hep-
atic cytochrome P450 enzymes, specifically via CYP2D6,
CYP2B6, CYP2C19, and CYP3A4. Even though MDMA is
ingested in its racemic form, metabolism of rac-MDMA
is stereoselective with (+)-(S)-MDMA being preferentially
metabolised [5, 6] and more potent in inducing euphoria
and energy [7, 8], whereas the (−)-(R)-MDMA exert higher
hallucinogen-like activity than the (+)-(S)-MDMA [9]. This
is evident in the stereoselectivity observed in the concentra-
tions of MDMA and related metabolites in urine and plasma
samples [10–14].
MDMA enantiomers exhibit different pharmacodynam-
ics due to differences in binding affinities to receptor sites.
(+)-(S)-MDMA is a more effective releaser of dopamine and
serotonin when compared to its antipode [15] and thus is
more closely linked to the neurotoxic effects of MDMA.
(−)-(R)-MDMA is associated with hallucinogenic properties
whereas (+)-(S)-MDMA is more stimulant-like in its effects
[9]. Furthermore, the rate of elimination of (+)-(S)-MDMA
is higher than that of (−)-(R)-MDMA [4, 10, 13, 16, 17].
The binding of a drug to plasma or serum proteins is
a major determinant of free drug concentrations in vivo
and thus has a large impact on the drug’s pharmacokinetics,
pharmacodynamics, and toxicology [18]. For chiral drugs,
especially those with different activities and effects associated
with each enantiomer, stereoselectivity in protein binding
is an important consideration. Among drugs that have
exhibited considerable stereoselectivity in protein binding are
warfarin [19], ibuprofen [20], and ketoprofen [21].
There is a significant lack of information regarding
plasma protein binding of MDMA in humans or animals. To
date, only one study has assessed protein binding of MDMA
in dog plasma with the fraction of MDMA bound to protein
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reported as 0.40 [22]. To our knowledge, no information
is available regarding stereoselectivity of MDMA protein
binding in humans, rats, and mice.
As stereoselectivity plays an important role in the phar-
macokinetics and pharmacodynamics of MDMA, an assess-
ment of stereoselectivity in protein binding was carried out.
In this study, stereoselective protein binding of rac-MDMA
using two different concentrations in human plasma and
mouse and rat sera was determined using an ultrafiltra-
tion approach. Using a stereospecific gas chromatography-
mass spectrometry (GC-MS) assay, the amounts of (−)-(R)-
MDMA and (+)-(S)-MDMA bound to plasma or serum
proteins were quantified.
2. Materials and Methods
2.1. Reagents and Materials. Methanolic drug standards of
rac-MDMA (1000 𝜇g/mL of free base) and rac-MDMA-
d5 (100 𝜇g/mL of free base) were purchased from Cer-
rilliant (Round Rock, TX, USA). Hexane was obtained
from Fisher Scientific (Hampton, NH, USA). Ethyl acetate
was purchased from Merck (Darmstadt, Germany). Tri-
ethylamine and phosphate-buffered saline (PBS) at pH
7.4 were purchased from Sigma-Aldrich (St. Louis, MO,
USA). The chiral derivatization reagent R-(−)-𝛼-methoxy-𝛼-(trifluoromethyl)phenylacetyl chloride [(R)-MTPCl] (Chi-
raSelect grade, 99% purity, 99.5 : 0.5 enantiomeric ratio) was
obtained from Sigma-Aldrich (St. Louis, USA). All reagents
and solvents were of analytical grade. Vivaspin 500 cen-
trifugal ultrafiltration devices (polyether sulfone membrane,
10 kDa molecular weight cut-off) were purchased from Sar-
torius Stedim (Gottingen, Germany).
Human plasmawas obtained from theHospital Universiti
SainsMalaysia blood bank. Rat (Sprague-Dawley) andmouse
(BALB/c) serum were obtained from the School of Pharma-
ceutical Sciences, Universiti Sains Malaysia. The plasma and
serum used in this study were sourced from three different
donors, pooled according to species, and adjusted to pH 7.4
before being used in further experiments.
2.2. Preparation of Chiral Derivatization Reagent (R-MTPCl).
Aliquots of 10 𝜇L R-MTPCl were transferred to 4.0mL
amber glass vials, sealed with PTFE-lined screw caps, and
stored at −20∘C. When required, a vial was thawed to room
temperature and diluted with 1mL of hexane to give a 1% v/v
solution of R-MTPCl in hexane.
2.3. Preparation of Working Solutions. A 20 𝜇g/mL rac-
MDMA solution was prepared. A second working solution
of 2 𝜇g/mL rac-MDMA was prepared from the 20 𝜇g/mL
working solution. An internal standard solution containing
10 ul 𝜇g/mL rac-MDMA-d5 was also prepared. All working
and internal standard solutions were stored in the dark at 4∘C
until required.
2.4. Determination of Nonspecific Binding and Stereoselective
Protein Binding Assay. The possibility of nonspecific bind-
ing of MDMA occurring in the ultrafiltration device and
stereoselective binding were evaluated at two concentrations
of rac-MDMA: 20 and 200 ng/mL. In this experiment, 0.01M
PBS at pH 7.4 was used as a surrogate matrix for plasma or
serum. PBS (495 𝜇L) was pipetted into 2mL microcentrifuge
tubes followed by the addition of 5 𝜇L of the appropriate
working solution. The final organic solvent concentration
was maintained at less than 1% to avoid protein precipita-
tion. Control samples with similar concentrations of rac-
MDMA were also prepared. The samples were vortex-mixed
thoroughly and incubated at 37∘C in a shaking water bath
for 20min. Next, the samples were transferred to the upper
portion of the ultrafiltration device using a glass Pasteur
pipette. The device was closed and tapped gently in order to
eliminate any air bubbles. Control samples were transferred
to microcentrifuge tubes. The ultrafiltration devices and
control sampleswere centrifuged in a fixed-rotor centrifuge at
1000×g, 37∘C for 20min. After centrifugation, the upper por-
tion of the ultrafiltration device was removed and discarded.
Separate aliquots of 300 𝜇L each were removed from the
ultrafiltrate in the lower portion of the ultrafiltration device
as well as from the control samples and transferred to clean
screw-cap glass tubes. Each assay was performed in triplicate.
The concentrations of (−)-(R)-MDMA and (+)-(S)-MDMA
in the ultrafiltrate from each sample were determined as
described below.
2.5. Analytical Method. The samples were analysed using
a previously validated method which enables the stere-
oselective analysis of chiral amphetamine-type substances
using a GC-MS assay [23]. Using this method, the limit of
detection for MDMA was 10 𝜇g/L and recovery was more
than 80%. In brief, ten microliters of internal standard
working solution was added to the samples to be analysed.
The pH of the samples was adjusted to pH 10 with 2mL of
1.0M sodium carbonate. A solution of 2mL of hexane : ethyl
acetate 1 : 1 (v/v) containing 0.03% triethylamine was added
to the sample together with 150 𝜇L of the chiral derivatization
reagent (R-MTPCl).The sampleswere vortex-mixed for 1min
and then mixed on a rotary mixer at 40 rpm for 20min.
Subsequently, the samples were centrifuged at 3500 rpm for
5min and the upper organic layer was transferred to another
culture tube. The samples were dried on a heating block
at 40∘C under a gentle flow of nitrogen gas. The residue
was dissolved in 50 𝜇L of ethyl acetate before analysis using
GC-MS.
All samples were analysed using an Agilent (Santa Clara,
CA, USA) 6890 series gas chromatograph equipped with
a model 5973 mass selective detector. Injections were per-
formed using an Agilent autosampler (model 7893) and
injector. Separations were achieved using an Agilent HP-
5ms column (5% Phenyl-95% methylpolysiloxane stationary
phase; column dimensions: 15m, 250 𝜇m i.d., and 0.25 𝜇m
film thickness). The GC was operated with helium as carrier
gas with a flow of 1.0mL/min.The column oven was operated
as follows: being held at 150∘C for 1min, to 240∘Cat 10∘C/min,
and held for 5min, to 290∘C at 40∘C/min, and held for 1min
for a total run time of 17.25min. Samples were introduced
using a 4𝜇L pulsed splitless injection with the injector
port at 270∘C, 20 psi pressure pulse at 2min, and a purge
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Table 1: Percentage of nonspecific binding of rac-MDMA to ultrafiltration devices.
Concentration of rac-MDMA (ng/mL) Compound Mean peak area ratios Nonspecific binding (%)
Sample (𝑛 = 3) Control (𝑛 = 1)
20 (−)-(R)-MDMA 0.093 ± 0.019 0.091 −2.3
(+)-(S)-MDMA 0.098 ± 0.003 0.095 −3.1
200 (−)-(R)-MDMA 0.926 ± 0.076 0.884 −4.6
(+)-(S)-MDMA 0.940 ± 0.073 0.890 −5.6
time of 2min. The MS parameters were electron impact
ionization with an ion source temperature of 230∘C, transfer
line temperature of 280∘C, and a solvent delay of 5min. The
analysis was performed in selected ion monitoring (SIM)
mode.Them/z values monitored are as follows:m/z 274, 162,
and 136 forMDMA andm/z 278, 164, and 136 forMDMA-d5.
2.6. Determination ofNonspecific Binding andProtein Binding.
Equal volumes of ultrafiltrate and control sample (300 𝜇L)
were aspirated and analysed as described above. The amount
of each MDMA enantiomer in the samples was represented
by the peak area ratio of analyte [(−)-(R)-MDMA or (+)-
(S)-MDMA] to the respective internal standard [(−)-(R)-
MDMA-d5 or (+)-(S)-MDMA-d5].
The percentage of bound MDMA for both nonspecific
binding and protein binding was calculated according to the
following formula [24]:
Percent MDMA bound (%)
= 100
− [ (Peak area ratio in ultrafiltrate)(Peak area ratio in control sample) × 100] .
(1)
Stereospecificity in protein binding was determined by
calculating the R- to S-enantiomer ratio. Statistical signifi-
cance was determined using a paired t-test at a significance
level of 𝑝 < 0.05.
3. Results and Discussion
3.1. GC-MS Analysis. Under the analytical conditions used,
the enantiomers of MDMAwere separated with good resolu-
tion and sensitivity. The order of elution for the enantiomers
had been identified in a previous study to be (−)-(R)-MDMA
followed by (+)-(S)-MDMA [23, 25]. In the present study,
using comparison with pure R- and S-MDMA standards, it
was determined that the order of elution was the same.
3.2. Determination of Nonspecific Binding. Nonspecific bind-
ing of MDMA enantiomers to the ultrafiltration device
was estimated using 20 and 200 ng/mL of rac-MDMA. The
extractedMRMchromatograms obtained forMDMA-d5 and
MDMA at 20 ng/mL are shown in Figure 1. The choice of
20 and 200 ng/mL in the present study was based on a
previous study [26] to represent low and high concentrations,
respectively. For each of the concentrations assessed, it was
observed that the calculated percentages of nonspecific bind-
ing all gave negative values (Table 1) indicating that MDMA
enantiomers do not exhibit nonspecific binding to the walls
of the ultrafiltration device. Thus, it can be concluded that
the ultrafiltration device is suitable for determining protein
binding of MDMA.
3.3. Protein Binding of MDMA Enantiomers. In all exper-
iments, protein binding of rac-MDMA at concentrations
of 20 and 200 ng/mL was evaluated and the percentage
protein binding for each species was calculated (Table 2). In
human plasma, at a concentration of 20 ng/mL MDMA, it
was found that 41% and 44% of (−)-(R)-MDMA and (+)-
(S)-MDMA, respectively, were bound to plasma proteins. A
tenfold increase of MDMA to 200 ng/mL resulted in a slight
increase in binding to 51% for both (−)-(R)-MDMA and (+)-
(S)-MDMA.
In rat serum, it was found that, for both concentrations,
MDMA enantiomers were bound to serum proteins to a
similar extent as that of human plasma proteins. At 20 ng/mL
of rac-MDMA, 38% of (−)-(R)-MDMA and 41% of (+)-
(S)-MDMA were bound to serum proteins. Also, similar
to human plasma proteins, these values increased slightly
to 47% and 50% for (−)-(R)-MDMA and (+)-(S)-MDMA,
respectively, for 200 ng/mL of MDMA in rat serum. These
values are comparable to the bound fraction of 40% reported
for dog plasma [22].
In mouse serum, MDMA enantiomers were bound to
serum proteins at a lesser extent when compared to human
plasma or rat serum. At a concentration of 20 ng/mL, the
percentage of (−)-(R)-MDMA and (+)-(S)-MDMA bound to
serum proteins was 28% and 36%, respectively. As opposed
to the observations in human plasma and rat serum which
demonstrated a slight increase in the amount of protein-
bound MDMA with an increase in MDMA concentration,
mouse serum demonstrated a decrease in the percentage
of bound MDMA when the concentration of MDMA was
increased to 200 ng/mL, with only 11% (−)-(R)-MDMA and
15% of (+)-(S)-MDMA being bound to serum proteins. This
decrease indicates that it is likely that the binding sites for
MDMA on mouse serum proteins are saturated at lower
concentrations of MDMAwhen compared to that of humans
and rats. Therefore, in mice, a tenfold increase in MDMA
concentration did not result in an increase in protein-bound
MDMA.
Stereoselectivity in protein binding was estimated by
calculating the ratio of bound (−)-(R)-MDMA versus (+)-
(S)-MDMA for each matrix tested. A ratio of <1 indicates
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Figure 1: Extracted MRM chromatograms for (a) MDMA-d5 and (b) MDMA at 20 𝜇g/mL.
that (+)-(S)-MDMA is favoured during protein binding and a
ratio of >1 indicates that (−)-(R)-MDMA is favoured instead.
A ratio of 1 signifies that both (+)-(S)-MDMA and (−)-
(R)-MDMA are equally bound to plasma or serum proteins
and, thus, stereoselectivity in protein binding does not occur.
The stereoselectivity of protein binding for each species is
reported in Table 2.
For both human plasma and rat serum, the enantiomer
ratio was close to 1, with values ranging from 0.92 to 0.99 at
both concentrations of rac-MDMA tested.This indicates that
stereoselectivity in protein binding in both human plasma
and rat serum is negligible and both enantiomers of MDMA
are almost equally bound to plasma or serum proteins.
However, in mouse serum, there was significant stereos-
elective binding (paired 𝑡-test, 𝑝 < 0.05). The enantiomeric
ratios were 0.78 and 0.74 for 20 ng/mL and 200 ng/mL
of rac-MDMA, respectively. These ratios indicate that, in
mouse serum, stereoselective protein binding occurs with
(+)-(S)-MDMA being preferentially favoured over (−)-(R)-
MDMA.
Our data clearly shows that even though there is amarked
stereoselectivity in protein binding in the mice samples
when compared to that of human and rat samples, the total
protein binding for mice was very low (11–36%). Therefore
it is unlikely that the stereoselectivity of protein binding in
mice plays a significant role in the observed stereoselective
metabolism of MDMA in these species. This indicates that
even though mice can be used as animal model to study
stereoselective metabolism of MDMA in vitro, it should not
be used in studies that investigate protein binding.
4. Conclusion
Protein bindings of MDMA enantiomers in human plasma
and rat serum were found to be similar with percentages
between 38 and 51%. In mouse serum, however, protein
binding values were considerably lower at 11–36%. Stereos-
electivity was not evident in both human and rat serum,
whereas mouse serum exhibited considerable stereoselec-
tivity in protein binding with (+)-(S)-MDMA being bound
Journal of Chemistry 5
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to a higher extent compared to (−)-(R)-MDMA. However,
as protein binding for mice was rather low, it is unlikely
that the observed stereoselectivity would have a significant
effect on MDMA disposition in mice. Based on these results,
it can be concluded that protein binding of MDMA does
not contribute to stereoselective disposition of MDMA in
humans, rats, and mice. It should also be pointed out that
protein binding of MDMA in mouse serum is considerably
lower than in humans and rats and this factor should be taken
into account if mice are used for in vitro studies involving
MDMA.
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